Ex-Cin­Cor CEO Marc de Garidel lands at Abi­vax af­ter ne­go­ti­at­ing $1.8B cash sale

Three months af­ter sell­ing Cin­Cor and its hy­per­ten­sion drug to As­traZeneca for up to $1.8 bil­lion in cash, Marc de Garidel is back in a new CEO role.

As Abi­vax’s new chief, de Garidel suc­ceeds the com­pa­ny’s founder, Hart­mut Ehrlich, who’s set to re­tire af­ter a 10-year run capped by steer­ing Abi­vax to a Phase III tri­al.

The Cin­Cor deal stirred up some buzz at the JP Mor­gan con­fer­ence in San Fran­cis­co, as many held it up as a sign of M&A ac­tiv­i­ty amid a down­cy­cle for biotech in­vest­ment. It marked the sec­ond ma­jor deal in de Garidel’s ca­reer, hav­ing sold Cor­vidia Ther­a­peu­tics to No­vo Nordisk for $725 mil­lion up­front in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER